# Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Source: https://onco.cc/trials/nct05463601/  
OnCo record `nct05463601` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mecapegfilgrastim and Dalpiciclib in Breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, active and no longer recruiting.

## Summary

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer is a phase 2 interventional study registered as NCT05463601 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with 132 participants planned, started 2022-08-01 and due to reach its primary completion in 2025-01-31. Interventions recorded: Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen. Conditions recorded: Metastatic Breast Cancer.

Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05463601
- Phase: 2
- Setting: Efficacy and Safety of Mecapegfilgrastim for Prophylaxis of Dalpiciclib -Induced Neutropenia in Patients With Advanced HR+/HER2- Breast Cancer: a Open-label, Multicenter, Investigator-initiated, Randomized Controlled Phase II Trial
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT05463601: https://clinicaltrials.gov/study/NCT05463601

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Dalpiciclib](https://onco.cc/drugs/dalpiciclib/), [Mecapegfilgrastim](https://onco.cc/drugs/mecapegfilgrastim/)

---
JSON: https://onco.cc/api/v1/entities/nct05463601.json